Due to the possible regulation of the cGMP/PKG/CREB and cGMP/PKG/pGSK3 β pathways through the increase in levels of cGMP in the brain, PDE5 inhibitors appear to be good candidates for AD treatment. The gene discussed is PRKG1; the disease is Alzheimer disease.